NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02319135,Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT02319135,FLUGAZA,COMPLETED,"The hypothesis is that the replacement of the standard fludarabine and cytarabine based therapy by azacytidine could result in an improvement of RFS and OS rates in the experimental arm. To fulfill the medical needs in such frail and elderly population, improvements in terms of atileukemic efficacy in the azacytidine experimental arm should be attained without increasing the therapy-related toxicity or decreasing the patients QoL.",NO,Acute Myeloid Leukemia,DRUG: Azacitadine|DRUG: Fludarabine|DRUG: Cytarabine|DRUG: Lenograstim|DRUG: Filgastrim,"Efficacy (overall survival (OS) attained without increasing the therapy-related toxicity or decreasing the patients QoL., To evaluate the overall survival (OS) in one year treatment with 2 first-line regimens in newly diagnosed elderly patients: 3 cycles of induction chemotherapy based on fludarabine and cytarabine (FLUGA scheme) followed by maintenance with reduced doses(Mini-FLUGA) (standard treatment arm) versus subcutaneous azacitidine cycles (experimental treatment arm)., 4 years","Efficacy (Event free survival (EFS), Event free survival (EFS), 4 years|Efficacy (Duration of remission.), Duration of remission., 4 years|Efficacy (Overall survival) Efficcacy, Overall survival at 2nd and 3rd year., 3 years|Safety (Compare hematologic and non-hematologic toxicity), Compare hematologic and non-hematologic toxicity in both arms., 3 years",,PETHEMA Foundation,Dynamic Solutions,ALL,OLDER_ADULT,PHASE3,289,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,FLUGAZA,2014-10,2018-10-28,2019-10-28,2014-12-18,,2020-04-06,"Hospital Universitari i Politècnic La Fe, Valencia, 46026, Spain",
